Results 101 to 110 of about 69,057 (285)

Signaling Can Be Uncoupled from Imaging of the Somatostatin Receptor Type 2

Molecular Imaging, 2007
Endogenous and exogenous somatostatin receptors are commonly targeted for imaging using radiopharmaceutical analogues of somatostatin. Ligand binding activates receptor-mediated signaling.
Lin Han, Dan Yang, Vikas Kundra
doaj   +1 more source

A Transgenic Rat for Investigating the Anatomy and Function of Corticotrophin Releasing Factor Circuits. [PDF]

, 2015
Corticotrophin-releasing factor (CRF) is a 41 amino acid neuropeptide that coordinates adaptive responses to stress. CRF projections from neurons in the central nucleus of the amygdala (CeA) to the brainstem are of particular interest for their role in ...
Blasio, Angelo, Crawford, Elena, Dadgar, Jahan, De Guglielmo, Giordano, George, Olivier, Hopf, F Woodward, Janak, Patricia H, Keiflin, Ronald, Kharazia, Viktor, Maiya, Rajani, Messing, Robert O, Millan, E Zayra, Pomrenze, Matthew B, Rice, Kenner C   +13 more
core   +2 more sources

Staging metastatic urothelial cancer with Nectin‐4 imaging using Gallium‐68‐N188 PET/CT

BJU International, EarlyView.
Objective To quantify Nectin‐4 expression in tumour lesions using the Nectin‐4‐binding peptide Gallium‐68‐N188 and positron emission tomography (PET)/computed tomography (CT) in patients with advanced or metastasised urothelial cancer eligible for therapy with the Nectin‐4‐directed antibody–drug conjugate enfortumab vedotin, in combination with ...
Matthias Miederer, Marc Pretze, Elena Abbate, Andreas Hartig, Joana do Mar Ferreira Machado, Katharina Böhm, Ulrich Sommer, Sebastian Hoberück, Ralph A. Bundschuh, Jörg Kotzerke, Christian Thomas   +10 more
wiley   +1 more source

Supplementary table 1 from ¹⁷⁷Lu-DOTA-EB-TATE, a Radiolabeled Analogue of Somatostatin Receptor Type 2, for the Imaging and Treatment of Thyroid Cancer

, 2023
Shilpa Thakur, Brianna Daley, Corina Millo, Craig Cochran, Orit Jacobson, Huiyan Lu, Zhantong Wang, Dale O. Kiesewetter, Xiaohong Chen, Vasyl Vasko, Joanna Kłubo-Gwieździńska   +10 more
openalex   +1 more source

Psilocybin as a novel treatment for chronic pain

British Journal of Pharmacology, EarlyView.
Abstract Psychedelic drugs are under active consideration for clinical use and have generated significant interest for their potential as anti‐nociceptive treatments for chronic pain, and for addressing conditions like depression, frequently co‐morbid with pain.
Tate Askey, Reena Lasrado, Maria Maiarú, Gary J. Stephens   +3 more
wiley   +1 more source

Somatostatin receptor expression in multiple hemangiomas

Discover Oncology
Background Although hemangiomas frequently occur in the skin, mucosa, liver, and brain, they are rarely observed in the abdominal cavity or retroperitoneum.
Benjin Liu, Shangjian Li, Yisi Xu, Xuqi Huang, Xudong Guo, Hanbo Wang, Shaobo Jiang   +6 more
doaj   +1 more source

Novel approaches for drug development against chronic primary pain: A systematic review

British Journal of Pharmacology, EarlyView.
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus, Éva Borbély, Andreas Goebel, Ralf Baron, Zsófia Hajna, Zsuzsanna Helyes   +5 more
wiley   +1 more source

Paltusotine versus octreotide: different effects on radioligand uptake in neuroendocrine tumours

Endocrine Oncology
Objective: Somatostatin receptor analogues are well-established in the treatment of metastatic gastro-enteropancreatic neuroendocrine tumours (GEP-NETs), especially for symptom control in patients with the carcinoid syndrome, and to control tumour growth.
Katharina Wang, Christoph J Auernhammer, Simon Lindner, Mathias Zacherl, Rudolf A Werner, Julian Maurer, Lea Peischer, Julia Hamati, Maximilian P Hungbauer, Thomas Knösel, Astrid Reul, Elena Kuzmenko, Diana Vetter, José Oberholzer, Umberto Maccio, Felix Beuschlein, Martin Reincke, Constanze Hantel, Karel Pacak, Ashley B Grossman, Kathrin Zitzmann, Svenja Nölting   +21 more
doaj   +1 more source

The novel mTOR inhibitor RAD001 (Everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells [PDF]

, 2007
Background/Aim: Tumors exhibiting constitutively activated PI(3) K/Akt/mTOR signaling are hypersensitive to mTOR inhibitors such as RAD001 (everolimus) which is presently being investigated in clinical phase II trials in various tumor entities, including
Albert JM, Auernhammer CJ, Boulay A, Boulay A, Bousquet C, Burkhard Göke, Cao C, Christoph J. Auernhammer, Enrico N. De Toni, Faivre S, Gerald Spöttl, Grewe M, Heinrich H.D. Meyer, Hosoi H, Jeng YJ, Jennifer Meinecke, Kathrin Zitzmann, Kawamata S, Kirchner GI, Luo J, O?Reilly KE, Oberg K, Ramage JK, Sawyers CL, Shah T, Shaw RJ, Stephan Brand, Sun SY, Vignot S, von Wichert G, Wang L, Wanner K, Wendel HG, Wullschleger S, Yao JC, Yee KW   +35 more
core   +1 more source

Exploring Brain Parenchymal Changes in Acromegaly: Focus on White Matter Hyperintensities

Clinical Endocrinology, EarlyView.
ABSTRACT Introduction Acromegaly is a rare chronic disease caused by excessive secretion of growth hormone. Even with biochemical control, hormonal imbalance may lead to cerebral changes. This study aimed to evaluate the presence of white matter hyperintensities (WMHs) in patients with acromegaly.
Denise Costa, Giada Giuliani, Valentina Martines, Chiara Pellicano, Valeria Mercuri, Vittorio Di Piero, Patrizia Gargiulo, Camilla Virili   +7 more
wiley   +1 more source